RCM
ABCL icon

Ratan Capital Management’s AbCellera Biologics ABCL Stock Holding History

Ratan Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-47,265
Closed -$214K – 38
2024
Q1 		$214K Buy
+47,265
New +$241K 0.11% 39

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Ratan Capital Management's ABCL Position: Q2 2024 in Review

Ratan Capital Management sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 47,265 shares — an estimated $214K sold.

Ratan Capital Management first reported a position in ABCL in Q1 2024 and held it in 1 quarter. The position peaked at $214K in Q1 2024. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Ratan Capital Management reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Ratan Capital Management sold 47,265 AbCellera Biologics shares in Q2 2024, an estimated $214K.
  • Ratan Capital Management first reported a position in AbCellera Biologics in Q1 2024 and held it in 1 quarter.
  • Ratan Capital Management's AbCellera Biologics position peaked at $214K in Q1 2024.
  • 147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Ratan Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.